title: AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling.
abstract: BACKGROUND
  Heart failure is characterized by impaired function and disturbed Ca2+ homeostasis. Transgenic increases in inhibitor-1 activity have been shown to improve Ca2 cycling and preserve cardiac performance in the failing heart. The aim of this study was to evaluate the effect of activating the inhibitor (I-1c) of protein phosphatase 1 (I-1) through gene transfer on cardiac function in a porcine model of heart failure induced by myocardial infarction.
  
  
  RESULTS
  Myocardial infarction was created by a percutaneous, permanent left anterior descending artery occlusion in Yorkshire Landrace swine (n=16). One month after myocardial infarction, pigs underwent intracoronary delivery of either recombinant adeno-associated virus type 9 carrying I-1c (n=8) or saline (n=6) as control. One month after myocardial infarction was created, animals exhibited severe heart failure demonstrated by decreased ejection fraction (46.4±7.0% versus sham 69.7±8.5%) and impaired (dP/dt)max and (dP/dt)min. Intracoronary injection of AAV9.I-1c prevented further deterioration of cardiac function and led to a decrease in scar size.
  
  
  CONCLUSIONS
  In this preclinical model of heart failure, overexpression of I-1c by intracoronary in vivo gene transfer preserved cardiac function and reduced the scar size.
authors.affiliation: Department of Cardiology, Cardiovascular Research Center, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Fish
authors.forename: Dennis
authors.initials: D
authors.lastname: Ladage
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kawase
authors.forename: Ioannis
authors.initials: I
authors.lastname: Karakikes
authors.forename: Dongtak
authors.initials: D
authors.lastname: Jeong
authors.forename: Hung
authors.initials: H
authors.lastname: Ly
authors.forename: Kiyotake
authors.initials: K
authors.lastname: Ishikawa
authors.forename: Lahouaria
authors.initials: L
authors.lastname: Hadri
authors.forename: Lisa
authors.initials: L
authors.lastname: Tilemann
authors.forename: Jochen
authors.initials: J
authors.lastname: Muller-Ehmsen
authors.forename: R Jude
authors.initials: RJ
authors.lastname: Samulski
authors.forename: Evangelia G
authors.initials: EG
authors.lastname: Kranias
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Hajjar
mesh_terms: D000818:Animals; D000229:Dependovirus / Q000235:genetics*; D004195:Disease Models, Animal; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006333:Heart Failure / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D054645:Protein Phosphatase 1 / Q000096:biosynthesis* / Q000235:genetics; D020127:Recovery of Function; D013318:Stroke Volume; D013552:Swine; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D016277:Ventricular Function, Left; D017725:Ventricular Pressure; D020257:Ventricular Remodeling
chemical_list: D054645:Protein Phosphatase 1